Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours.
Medley L., Morel AN., Farrugia D., Reed N., Hayward N., Davies JM., Kirichek O., Thakker RV., Talbot DC.
BACKGROUND: This study sought to determine the safety of single agent capecitabine, a pro-drug of 5FU, in patients with metastatic non-pancreatic neuroendocrine tumours (NETs). METHODS: Multicentre phase II, first-line study design. Oral capecitabine was administered on days 1-14 of 3-week cycles. RESULTS: Treatment was safe and well tolerated. Common toxicities were diarrhoea and fatigue. CONCLUSION: The study provides evidence to support the use of capecitabine as a substitute for infusional 5FU in the management of NETs.